Paresh Dandona, said, referring to two types of insulin, one fast-acting and used to blunt blood sugar spikes after eating, and the other more long-acting, meant to keep blood sugar steady throughout the day
Diabetes Investigation 14 (2), 247258
"The positive ACHIEVE-1 results position orforglipron as a potential treatment option with meaningful A1C and weight reduction, and a safety profile similar to injectable GLP-1 therapies." Lilly and others are trying to develop oral therapies to complement current blockbuster drugs Novo Nordisk's Ozempic (semaglutide) and Lilly's dual GIP/GLP-1 agonist Mounjaro (tirzepatide) which are given by weekly injection to treat type 2 diabetes
The LifeVantage system has two small, unblinded studies and relies on briefly boosting a hormone that degrades in minutes
One reviewer notes that the product has helped alleviate digestive issues, saying, "I have noticed a definite change with my stomach problems